TABLE 2.
Summary of dalbavancin activity tested against S. aureus isolates with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. medical centers
| Resistance phenotype | No. of isolates (cumulative %) inhibited at dalbavancin MIC (mg/liter) ofa: |
MIC50 (mg/liter) | MIC90 (mg/liter) | ||||
|---|---|---|---|---|---|---|---|
| ≤0.03 | 0.06 | 0.12 | 0.25 | 0.5 | |||
| Vancomycin MIC ≥2 mg/liter (n = 1,141) | 117 (10.3) | 697 (71.3) | 276 (95.5) | 43 (99.3) | 8 (100.0) | 0.06 | 0.12 |
| Daptomycin nonsusceptible (n = 48) | 3 (6.3) | 25 (58.3) | 16 (91.7) | 2 (95.8) | 2 (100.0) | 0.06 | 0.12 |
| Telavancin MIC ≥0.12 mg/liter (n = 52)b | 4 (7.7) | 24 (53.8) | 16 (84.6) | 3 (90.4) | 5 (100.0) | 0.0.6 | 0.25 |
| Teicoplanin MIC ≥4 mg/liter (n = 143) | 14 (9.8) | 73 (60.8) | 33 (83.9) | 16 (95.1) | 7 (100.0) | 0.06 | 0.25 |
| Linezolid resistant (n = 25) | 5 (20.0) | 18 (92.0) | 2 (100.0) | 0.06 | 0.06 | ||
| All isolates (n = 59,903) | 22,066 (36.8) | 33,879 (93.4) | 3,795 (99.7) | 155 (>99.9) | 8 (100.0) | 0.06 | 0.06 |
a
Boldface data represent dalbavancin modal MIC results. The dalbavancin-susceptible breakpoint approved by the FDA for S. aureus is ≤0.25 mg/liter (13).
b
Telavancin was only tested against isolates collected in 2011 to 2016.